Filing Flows

Filing Flows › Companies › Spruce Biosciences › Cash flow

Spruce Biosciences cash flow, quarter by quarter

Latest: Q2 2026 · from the cash-flow statements filed with the SEC

Free cash flow−$22.3M in Q2 2026 · −$42.6M over twelve months

Operating cash flow−$22.1M
Capital spending−$135K
Free cash flow−$22.3M

Analysis

In Q2 2026, Spruce Biosciences generated −$22.1M of operating cash flow and spent $135K on capital projects, leaving free cash flow of −$22.3M. That is $13.4M less than in Q2 2025 (−$8.8M).

Over the twelve months to Jun 30, 2026, operating cash flow was −$42.6M; the largest uses were operating cash flow ($42.6M), net borrowing (+) / repaid (−) ($1.2M), taxes on employees’ shares ($841K); besides operations, cash came from other financing ($125M), shares issued ($27K); the cash balance rose by $79.9M.

Operating cash flow was −$22.1M against net income of −$16.2M. The largest differences: prepaid and other assets −$3.9M, payables −$1.4M, stock-based pay +$871K.

Free cash flow

Spruce Biosciences: free cash flow by quarterSpruce Biosciences: free cash flow by quarter−$9.2MQ3 2024−$20.7MQ4 2024−$12.7MQ1 2025−$8.8MQ2 2025−$5.3MQ3 2025−$6.5MQ4 2025−$8.7MQ1 2026−$22.3MQ2 2026
Operating cash flow less capital spending.
Spruce Biosciences: operating cash flow against capital spendingSpruce Biosciences: operating cash flow against capital spendingOperating cash flowCapital spending−$9.2M$0Q3 2024−$20.7M$0Q4 2024−$12.7M$0Q1 2025−$8.8M$0Q2 2025−$5.3M$0Q3 2025−$6.5M$0Q4 2025−$8.7M$10KQ1 2026−$22.1M$135KQ2 2026
Latest (Q2 2026): Operating cash flow −$22.1M, Capital spending $135K.

Capital allocation, year by year

Spruce Biosciences: where the cash came from (up) and went (down), by fiscal yearSpruce Biosciences: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedCapital spendingFY2021: Operating cash flow −$35.9MFY2021: Net borrowing $220KFY2021: Shares issued $328KFY2021: Capital spending −$93K$548KFY2021FY2022: Operating cash flow −$41.7MFY2022: Shares issued $2KFY2022: Capital spending −$8K$2KFY2022FY2023: Operating cash flow −$33.3MFY2023: Net borrowing −$1.6MFY2023: Shares issued $1KFY2023: Capital spending −$7K$1KFY2023FY2024: Operating cash flow −$56.0MFY2024: Net borrowing −$1.6MFY2024: Shares issued $180K$180KFY2024FY2025: Operating cash flow −$33.3MFY2025: Net borrowing −$2.1MFY2025: Shares issued $5K$5KFY2025
Over these 5 years operating cash flow totalled −$200M; the largest uses were operating cash flow ($200M) and net borrowing ($5.3M). Cash-flow statements as filed.

Where the cash came from and went

Spruce Biosciences: sources (+) and uses (−) of cash, Q2 2026Spruce Biosciences: sources (+) and uses (−) of cash, Q2 2026Other financing$64.5MCash drawn (+) / kept (−)−$42.2MOperating cash flow−$22.1MCapital spending−$135K
Spruce Biosciences: sources (+) and uses (−) of cash, TTM to Q2 2026Spruce Biosciences: sources (+) and uses (−) of cash, TTM to Q2 2026Other financing$125MCash drawn (+) / kept (−)−$79.9MOperating cash flow−$42.6MNet borrowing (+) / repaid (−)−$1.2MTaxes on employees’ shares−$841KNot reconciled−$145KShares issued$27K

From profit to cash

Spruce Biosciences: net income to operating cash flow, Q2 2026Spruce Biosciences: net income to operating cash flow, Q2 2026Net income−$16.2MDepreciation & amortization$631KStock-based pay$871KPayables−$1.4MAccrued liabilities−$589KPrepaid and other assets−$3.9MOther liabilities−$87KOperating cash flow−$22.1M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.

Every quarter

QuarterOperating cash flowCapital spendingNet borrowing (+) / repaid (−)Shares issuedCash drawn (+) / kept (−)Free cash flow
Q2 2026−$22.1M−$135K——−$42.2M−$22.3M
Q1 2026−$8.7M−$10K$14.1M—−$5.2M−$8.7M
Q4 2025−$6.5M—−$841K$5K−$38.2M−$6.5M
Q3 2025−$5.3M—−$405K—$5.7M−$5.3M
Q2 2025−$8.8M—−$406K—$9.2M−$8.8M
Q1 2025−$12.7M—−$405K—$13.1M−$12.7M
Q4 2024−$20.7M—−$406K—$21.3M−$20.7M
Q3 2024−$9.2M—−$405K—$9.6M−$9.2M

Spruce Biosciences: income statement and cash flow

Spruce Biosciences, Q4 2024: revenue $697K (-76% year over year). The chart follows the revenue to costs, profit and cash.

Spruce Biosciences: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.